HR Manager

Principal/Senior Scientist, Analytical Science

Human Resources Director

Senior Consultant, CMC Development and Manufacturing

1910 Genetics

20n Bio

3DBio Therapeutics

3T Biosciences

4D Molecular Therapeutics

64x Bio

76Bio

A-Alpha Bio

A2 Biotherapeutics

AAVogen

ACELYRIN

ADAXION Therapeutics

AI Proteins

AIRNA Bio

ALX Oncology

AN2 Therapeutics

AOA Dx

ARTBIO

AS2 Bio Inc

AUM BioTech

AVROBIO

Ab Studio

Abalone Bio

Abata Therapeutics

Abeona Therapeutics

Abintus Bio

Abiosciences

Absci

Accelevir Diagnostics

Accent Therapeutics

Acepodia

Achieve Life Sciences

Acomhal Research

Acrivon Therapeutics

Actym Therapeutics, Inc.

Acutis Diagnostics

Adaptive Phage Therapeutics

Adcentrx Therapeutics

Adicet Bio

Adiso Therapeutics

Aditum Bio

Admera Health

Adverum Biotechnologies

Aeglea BioTherapeutics

Aera Therapeutics

Aether Bio

Affini-T Therapeutics

Affinia Therapeutics

AgBiome

Agastiya Biotech

Agena Bioscience

AiViva Biopharma

Ainnocence

AivoCode

Aixa Bio

Akero Therapeutics

Akita Biosciences

Akouos

Akttyva Therapeutics

Alamar Biosciences

Aldebaran Therapeutics

Alector

Alida Biosciences

AlivaMab Discovery Services

Alkahest

Alladapt Immunotherapeutics

Allarta Life Science

Allay Therapeutics

AlloVir

Alloy Therapeutics

Alltrna

AlpaLifeBio

Alpha-9 Oncology

Alphabioregen

AltPep

Alterome Therapeutics

Altis Biosystems

Alto Neuroscience

Alumis

Alveo Technologies

Alveolus Bio

Alzheon

AmbAgon Therapeutics

Amberstone Biosciences

Amolyt Pharma

Amylyx Pharmaceuticals

AnHeart Therapeutics

Anagram Therapeutics

Ancora Biotech LLC

Andes

Andson Biotech

Anebulo Pharmaceuticals

Angiex

Angiocrine Bioscience

Anima Biotech

Ankyra

Annexon Biosciences

Anodyne Nanotech

Anokion

Ansa Biotechnologies

GenEdit is developing safe and efficient gene editing. Delivery remains a major challenge for gene editing therapies and limits the therapies’ performance. To improve delivery, GenEdit has developed a delivery platform called NanoGalaxy, which contains a library of unique non-viral, non-lipid, polymer nanoparticles that can be used as vectors for gene therapies. Polymer backbones are combined with small molecules to create a vast polymer diversity which GenEdit screens. Diversity in charge, size and composition offers a unique array of properties that affect the tissue-targeting specificity and durability. GenEdit is primarily interested in the lung, CNS and immune system for tissue targeting. By targeting these tissues selectively, GenEdit aids in the development of therapeutics for patients with high unmet medical need.

<p>GenEdit is developing safe and efficient gene editing. Delivery remains a major challenge for gene editing therapies and limits the therapies’ performance. To improve delivery, GenEdit has developed a delivery platform called NanoGalaxy, which contains a library of unique non-viral, non-lipid, polymer nanoparticles that can be used as vectors for gene therapies. Polymer backbones are combined with small molecules to create a vast polymer diversity which GenEdit screens. Diversity in charge, size and composition offers a unique array of properties that affect the tissue-targeting specificity and durability. GenEdit is primarily interested in the lung, CNS and immune system for tissue targeting. By targeting these tissues selectively, GenEdit aids in the development of therapeutics for patients with high unmet medical need.</p>


Find a biotech startup job.